The digital revolution has in recent years transformed the global healthcare sector. The emergence of innovative technology has given rise to a network of diagnostic devices that can be used to generate, collect, and analyze huge volume of medical data. This in turn allows physicians to better measure and observe patients’ health, making diagnosis processes more efficient and accurate. Yet there are still plenty of gaps in diagnostic technology. For example, the recent pandemic underscores the demand for more options for effective and comprehensive detections systems for viruses and bacteria linked to respiratory infections. As such, Avalon has joined hands with researchers at top universities in Hong Kong to develop solutions aimed at enhancing early detection of conditions from COVID-19 to genetic diseases to cancer. 

OUR Solutions

Early Detection of infectious respiratory diseases

In general, current tests can only identify one to three types of bacteria or virus at one time. If you need to check for 40 pathogens, you either get 40 people to perform tests or do the tests 40 times.

Professor Terence Lau, Former Director of Innovation and Technology Development at Hong Kong Polytechnic University

With a single test, our all-in-one, fully automated diagnostic system can detect up to 40 pathogens, including COVID-19 and severe acute respiratory syndrome coronavirus (SARS-CoV), in around an hour. In addition, new technologies adopted by the system significantly enhances the reliability of test results while bringing substantial cost-saving, making it easier for wide adoption. This medical technological breakthrough is the result of the collaboration between Emerging Viral Diagnostics, a unit of Avalon, and research teams at the Hong Kong Polytechnic University and the University of Hong Kong.



Viruses, Bacteria and Fungi can be detected simultaneously


From sample extraction, amplifications, detection to analysis in one single device


5 gene copies with highly specific results


High epidemiological relevance with know-how on respiratory pathogens


Can be expanded to multiple platforms, other medical and non-medical applications


Understand your genes for better health

Our health monitoring service goes beyond genetic test results into offering personalized guidance from our team of medical professionals, with the goal of helping you maintain lifelong health. We strive to achieve this through the following features that distinguish us from similar genome sequencing services available globally.

  • State-of-the-art DNA analyzing systems built specifically for Asians at our own genetic laboratory in Hong Kong.
  • A Southern-Chinese Genomic Database aimed at offering more relevant and reliable genetic testing service for our targeted population.

Sogen – Preventive Health Management 

Developed by our team at Avalon Genomics, Sogen examines and analyzes the genetic risks of over 30 common conditions, including cancers and autoimmune diseases, in three easy steps. In addition, it provides a report with customized health improvement advice which allows you to take precautionary measures to reduce the chances of disease manifestation.


We are developing cancer diagnosis solution that is ultra-fast, blood-based and label-free.

Dr Andy Lau, Scientific Officer at Conzeb

The primary goal for the team at Conzeb is to address challenges faced by the medical community in cancer diagnostics and treatment monitoring, as current technologies adopted in this field are often costly, time-consuming and expert-dependent. The project, started at the University of Hong Kong and it’s now part of the Avalon platform, focuses on developing cancer diagnostic tools based on our revolutionary, patented ultra-fast optical imaging technologies –  ATOM and FACED – for label-free, blood-based single-cell imaging. Together with our ultra-high speed microfluidics and deep cyto-analytics, our technologies can be served as a big-data single-cell data generator – serving the needs of cost-effective, real-time analysis of thousands to millions of cells for each patient.